# Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)

Study · id `cardio:ct-nct07682922` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07682922](<https://clinicaltrials.gov/study/NCT07682922>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07682922

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1040 participants.

## Technical summary

Registry record NCT07682922. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-07-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1040 participants (planned count; ClinicalTrials.gov record NCT07682922, source copy `cardio:ctgov-nct07682922-2026-07-06`, retrieved 2026-10-26)
- Planned start: 2026-07-01 (anticipated) (ClinicalTrials.gov record NCT07682922, source copy `cardio:ctgov-nct07682922-2026-07-06`, retrieved 2026-10-26)
- Primary completion: 2028-07-01 (anticipated) (ClinicalTrials.gov record NCT07682922, source copy `cardio:ctgov-nct07682922-2026-07-06`, retrieved 2026-10-26)
- Completion: 2028-09-30 (anticipated) (ClinicalTrials.gov record NCT07682922, source copy `cardio:ctgov-nct07682922-2026-07-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07682922, source copy `cardio:ctgov-nct07682922-2026-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07682922-2026-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)
- Acronym: SLEDAIS
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Edaravone dexborneol sublingual tablet
- Intervention (Drug): Placebo
- Lead sponsor: Xinqiao Hospital of Chongqing
- Lead sponsor class: OTHER
- Collaborator: Simcere Pharmaceutical Group Co., LTD
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Xinqiao Hospital of Chongqing (`cardio:org-xinqiao-hospital-of-chongqing`)

## Provenance

Content hash: 2733c3c1df33cce5de2a210a874033d9c80024faf313ecc018ca9c8b77e74e39
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
